Both Ciclosporin, Methotrexate Effective for Severe Eczema in Children
Medically reviewed by Drugs.com.
By Elana Gotkine HealthDay Reporter
TUESDAY, Sept. 26, 2023 -- For children and young people with severe atopic dermatitis (AD), ciclosporin (CyA) and methotrexate (MTX) are both effective over 36 weeks, according to a study published online Sept. 19 in the British Journal of Dermatology.
Carsten Flohr, Ph.D., from Guy's and St. Thomas' NHS Foundation Trust and King's College London, and colleagues compared the safety and efficacy of CyA versus MTX in children and young people with severe AD. Eligible participants were aged 2 to 16 years and were unresponsive to potent topical treatment. One hundred three participants were randomly assigned to oral CyA (4 mg/kg/day) or MTX (0.4 mg/kg/week) for 36 weeks (52 and 51 patients, respectively).
The researchers observed greater improvement in disease severity by 12 weeks with CyA (mean difference Objective Severity Scoring of Atopic Dermatitis [o-SCORAD], −5.69). A 50 percent decrease in o-SCORAD (o-SCORAD-50) was reached by more participants in the CyA than MTX arm at 12 weeks (odds ratio, 2.60). MTX was superior by 60 weeks (odds ratio, 0.33); a trend was also seen for o-SCORAD-75, 50 percent reduction from baseline in the Eczema Area and Severity Index (EASI-50), and EASI-75. The CyA arm had higher participant-reported flares posttreatment (odds ratio, 3.22). Improvement in quality of life was seen with both treatments and was sustained after cessation of treatment. Both treatments had comparable frequency of adverse events.
"The TREAT trial demonstrated that both CyA and MTX are effective well-tolerated treatments for children and young people with severe AD," the authors write. "CyA acts more quickly, while MTX induces better disease control after treatment discontinuation."
Several authors disclosed ties to the pharmaceutical industry.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted September 2023
Read this next
Coexistence of Psoriatic Arthritis, Atopic Dermatitis May Offer Treatment Insights
MONDAY, May 13, 2024 -- Psoriatic arthritis (PsA) and atopic dermatitis (AD) can coexist, and the presence of both conditions may mean special attention should be given to...
Systemic Antibiotics in First Year of Life Tied to Higher Atopic Dermatitis Risk
WEDNESDAY, May 8, 2024 -- Systemic antibiotic exposure in the first year of life is associated with higher atopic dermatitis (AD) risk in a dose-response fashion, according to a...
Stigma Affects Quality of Life in Children With Chronic Skin Conditions
TUESDAY, April 30, 2024 -- Health care professionals should consider stigmatization and bullying in assessing the social and mental health of children and adolescents with chronic...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.